A Targeted Approach To Remove Tumor Cells By Filtration
Blood Transfusions (BT) are necessary when a patient loses a high amount of blood and the haematocrit becomes low in a surgical procedure.
Intraoperative Blood Salvage (IBS) is a technique frequently used during surgeries having a great potential for large blood loss to reduce or avoid allogeneic red blood cell transfusions with the associated risks and costs. As blood becomes more and more a rare commodity, surgeries are increasingly cancelled due to a lack of available matched blood.
Main benefits of Autologous Salvaged Blood for patients and physicians are:
does not result in immunological challenges and associated safety issues,
provides a higher quality of red blood cells
avoids the risk of acquired virus infections due to test failures or untested virus species and
is immediately available
Blood salvage and transfusion is common in major surgeries but currently not in oncological surgeries, due to cancer cells present in the majority of erythrocyte concentrates (EC) derived from intraoperative blood. Those cells could lead to new cancer metastasis.
Risk Reduction for Tumor Patients and Physicians
No risk of transfusion reactions due to incompatibility e.g. TRALI (transfusion related acute lung injury)
No risk of transmitted disease, such as Hepatitis, CMV, HIV, etc.
No downregulation of patients’ immune system
Our Solution
Lindis Blood Care has taken up the challange of reducing the negative effects of donor blood administration during surgical tumor removal by developing and manufacturing a new medical device that allows the save retransfusion of patients own blood.
Lindis Blood Care removes cancer cells from patient´s intraoperative blood for retransfusion. For that purpose we are developing the medical device, CATUVAB®
CATUVAB® is intended to be used as an add on in combination with the best practice methods.
Our patented technology CATUVAB® is based on inducing cell complexes with tumor cells and removing them by centrifugation and filtration by involving technical equipment (IBS device) that is currently available at nearly all hospitals.
CATUVAB®
First device to remove reliably cancer
cells from intraoperative blood
The CATUVAB® kit is a breakthrough medical device
Inducing tumor cell / lymphocyte complexes
Remove the complexes which are now much bigger than blood cells in an IBS procedure
Enable re-transfusion of tumor cell depleted intraoperative blood to the patient
Used together with technical equipment (IBS) already available in most hospitals
Advantages In Clinical Use
Benefits of Autologous Blood Salvage over allogeneic blood:
The patient’s blood is instantly available for re-infusion
No immunosuppression due to allogeneic blood/ erythrocytes reduced incidence of postoperative infections
No cross matching of blood types required and mistransfusion is eliminated
Based on literature data, LBC expects a potential to increase chance of prolonged relapse free – and overall survival time of cancer patients
Pharmacoeconomics
Cost-effective compared to fully burdened allogeneic blood transfusion
No costs for treatment of the possible severe side effects associated with allogeneic blood transfusions